Next Article in Journal
Hedgehog Signaling Inhibitors as Anti-Cancer Agents in Osteosarcoma
Next Article in Special Issue
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Previous Article in Journal
Lymphoma: Immune Evasion Strategies
Previous Article in Special Issue
cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance
Article Menu

Export Article

Open AccessReview
Cancers 2015, 7(2), 763-783; doi:10.3390/cancers7020763

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

1
Department of Clinical Pharmaceutics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan
2
Department of General Internal Medicine 4, Kawasaki Medical School, Okayama 700-8505, Japan
3
Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama 700-8558, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Siow Ming Lee
Received: 28 February 2015 / Revised: 14 April 2015 / Accepted: 21 April 2015 / Published: 30 April 2015
(This article belongs to the Special Issue Non-Small Cell Lung Cancer Therapies)
View Full-Text   |   Download PDF [711 KB, uploaded 30 April 2015]   |  

Abstract

The discovery of an echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene led to improved clinical outcomes in patients with lung cancer after the development of the first ALK-targeting agent, crizotinib. Some second-generation ALK tyrosine kinase inhibitors (TKIs), which might be more potent than crizotinib or effective on crizotinib-resistant patients, have been developed. Although these ALK-TKIs show an excellent response initially, most patients eventually acquire resistance. Therefore, careful consideration of the resistance mechanisms might lead to superior therapeutic strategies. Here, we summarize the history of ALK-TKIs and their underlying resistance mechanisms in both the preclinical and clinical settings. In addition, we discuss potential future treatment strategies in ALK-TKI-naïve and -resistant patients with lung cancer harboring the EML4-ALK fusion gene. View Full-Text
Keywords: lung cancer; EML4-ALK; crizotinib; ceritinib; alectinib; resistance lung cancer; EML4-ALK; crizotinib; ceritinib; alectinib; resistance
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Isozaki, H.; Takigawa, N.; Kiura, K. Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers 2015, 7, 763-783.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top